Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- IMMX
- Price
- 5.25
- Stock movement up
- +0.36 (7.36%)
- Company name
- Immix Biopharma Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 276.65M
- Ent value
- 272.52M
- Price/Sales
- 2873.11
- Price/Book
- 33.47
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 166.50%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IMMX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2873.11 |
| Price to Book | 33.47 |
| EV to Sales | 2830.20 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 52.70M |
| EPS (TTM) | -0.74 |
| FCF per share (TTM) | -0.48 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 96.29K |
| Gross profit (TTM) | -90.87K |
| Operating income (TTM) | -24.05M |
| Net income (TTM) | -23.56M |
| EPS (TTM) | -0.74 |
| EPS (1y forward) | -0.65 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -94.37% |
| Operating margin (TTM) | -24976.90% |
| Profit margin (TTM) | -24470.70% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 15.95M |
| Net receivables | 0.00 |
| Total current assets | 16.58M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 3.61M |
| Total assets | 20.08M |
| Accounts payable | 7.05M |
| Short/Current long term debt | 1.11M |
| Total current liabilities | 10.85M |
| Total liabilities | 11.82M |
| Shareholder's equity | 8.26M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -14.38M |
| Capital expenditures (TTM) | 1.07M |
| Free cash flow (TTM) | -15.45M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -285.09% |
| Return on Assets | -117.34% |
| Return on Invested Capital | -280.30% |
| Cash Return on Invested Capital | -183.81% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.90 |
| Daily high | 5.28 |
| Daily low | 4.89 |
| Daily Volume | 1.20M |
| All-time high | 7.38 |
| 1y analyst estimate | 7.95 |
| Beta | 0.33 |
| EPS (TTM) | -0.74 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 25 Feb 2026 |
Downside potential
Loading...
Downside potential data
| IMMX | S&P500 | |
| Current price drop from All-time high | -28.86% | -0.89% |
| Highest price drop | -81.29% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -64.59% | -2.49% |
| Avg time to new high | 322 days | 6 days |
| Max time to new high | 294 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
276.65M
Marketcap category
Small-cap
Description
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Employees
18
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page